Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070933 | 0.77 | CDC7 (0.42) | GRM4RETKDRKDM4EMAPT | |
| SCHEMBL13636079 | 0.76 | GRM4 (0.53) | GRM4RETKDRKDM4EMAPT | |
| SCHEMBL5068326 | 0.74 | KDM4E (0.40) | RETKDRKDM4EMAPTHTT | |
| SCHEMBL13636063 | 0.73 | GRM4 (0.52) | GRM4RETKDRKDM4EMAPT | |
| SCHEMBL12431099 | 0.70 | GRM4 (0.54) | GRM4RETKDRKDM4EMAPT | |
| SCHEMBL12431087 | 0.68 | GRM4 (0.51) | GRM4RETKDRKDM4EMAPT | |
| SCHEMBL5069223 | 0.67 | PLK4 (0.43) | KDM4EMAPTHTTKMT2AAURKA | |
| SCHEMBL20475759 | 0.66 | KDM4E (0.66) | RETKDRKDM4EMAPTHTT | |
| SCHEMBL30450716 | 0.65 | KMT2A (0.49) | RETKDRKDM4EMAPTHTT | |
| SCHEMBL14323070 | 0.65 | KDR (0.47) | RETKDRKDM4EMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304414-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-06 | — | — | US | claimed |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | claimed |
| EP-1345929-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-05-17 | — | — | EP | claimed |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | BEBBINGTON DAVID (GB) | 2004-08-12 | — | — | US | claimed |
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GRM4 4627/4885RET 898/4885KDR 2394/4885 |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | GRM4 4721/4885RET 680/4885KDR 2394/4885 |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GRM4 4664/4885RET 827/4885KDR 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.